TICKERNERD
Menu
LNTHLNTHHealthcare · Drug Manufacturers - Specialty & Generic

LNTH Stock Forecast: Lantheus Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$101
+0.01% on the day

The 11 Wall Street analysts covering Lantheus Holdings, Inc. hold a median 12-month price target of $105 — +4.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.6B
Ticker Nerd rank
88 / 100
Median analyst target
$105
Analysts covering
11
Total return, dividends reinvested
1W
0.0%
1M
−1.4%
YTD
+51.7%
1Y
+85.3%
From 52W high
−9.0%
From 52W low
+101.5%
$50
$111
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LNTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lantheus Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Value
91
Revisions
80
Issuance
76
Quality
75
Momentum
64
Growth
53
Accruals
53
Size
21

Volatility (93): The share price has been relatively steady.

Accruals (53): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LNTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LNTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26LNTHHigh $115Median $105Low $103

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
4 Buy7 Hold0 Sell
Low $103Median $105High $115

The green dot is the last close — the median target sits +4.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
4 Aug 2026CJS SecuritiesDowngradeMarket Perform—
4 Aug 2026Truist SecuritiesDowngradeHold$125 → $103
3 Aug 2026TD CowenDowngradeHold$110 → $103
3 Aug 2026William BlairDowngradeMarket Perform—
29 July 2026MizuhoMaintainsOutperform$120 → $115
16 July 2026Truist SecuritiesMaintainsBuy$115 → $125
16 July 2026Truist SecuritiesMaintainsBuy—
15 July 2026MizuhoMaintainsOutperform$115 → $120
15 July 2026MizuhoMaintainsOutperform—
9 July 2026B. Riley SecuritiesMaintainsBuy$97 → $129
9 July 2026B. Riley SecuritiesMaintainsBuy—
29 June 2026CitizensReiteratesMarket Outperform—
27 May 2026MizuhoMaintainsOutperform—
11 May 2026Truist SecuritiesReiteratesBuy—
8 May 2026CitizensMaintainsMarket Outperform—
8 May 2026MizuhoMaintainsOutperform—
15 Apr 2026Truist SecuritiesMaintainsBuy—
13 Apr 2026MizuhoMaintainsOutperform—
2 Mar 2026Truist SecuritiesMaintainsBuy—
27 Feb 2026CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LNTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LNTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.7%
Analysts raising
1
Analysts cutting
2
Fundamentals

Lantheus Holdings, Inc. (LNTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.2×

Cheaper than 33% of US stocks

Price / sales
4.2×

Cheaper than 30% of US stocks

Price / book
5.4×

Cheaper than 20% of US stocks

EV / EBITDA
16.9×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
2.7%

Higher than 34% of US stocks

Earnings growth (YoY)
−4.7%

Higher than 30% of US stocks

Gross margin
62.3%

Higher than 76% of US stocks

Operating margin
25.8%

Higher than 84% of US stocks

Net margin
17.7%

Higher than 81% of US stocks

Returns & dividend
Return on equity
22.2%

Higher than 83% of US stocks

Return on assets
8.4%

Higher than 89% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LNTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
LNTHLantheus Holdings, Inc.$6.6B
88
HIMSHims & Hers Health, Inc.$6.6B
17
LQDALiquidia Corp.$6.4B
78
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98
AMRXAmneal Pharmaceuticals, Inc.$5.7B
79
ALKSAlkermes Plc$8.1B
60
INDVIndivior Pharmaceuticals, Inc.$4.6B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lantheus Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LNTH news & analysis

US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

Reuters · 14 Aug 2026positive

The U.S. FDA approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company announced on Friday. The approval covers the agent's use in evaluating patients for the disease.

Why it matters — FDA approval of a Lantheus imaging agent could expand the company's product offerings in the Alzheimer's diagnostic space, a key growth area for LNTH.

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease

GlobeNewsWire · 14 Aug 2026positive

Lantheus Holdings announced that the U.S. Food and Drug Administration approved TAUKLARIFY (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for PET imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer's disease, to identify patients with tau neurofibrillary tangle pathology. The agent carries a limitation of use, as its safety and effectiveness have not been established for evaluating non-Alzheimer's disease tauopathies.

Why it matters — This FDA approval expands Lantheus's radiopharmaceutical portfolio by adding a new tau PET imaging agent for Alzheimer's disease evaluation, a development directly relevant to LNTH watchers tracking the company's commercial product lineup.

Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH

Business Wire · 7 Aug 2026neutral

Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti Jr., is investigating the proposed sale of Lantheus Holdings to Curium US Holdings LLC over the adequacy of the price and process. Under the proposed terms, Lantheus shareholders would receive $102.50 per share in cash plus non-transferable Contingent Value Rights of up to $12.00 per share in potential additional cash payments.

Why it matters — A LNTH watcher would care because the law firm's investigation could challenge or add scrutiny to the proposed acquisition of the company.

Lantheus Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 6 Aug 2026neutral

Lantheus Holdings reported second-quarter 2026 financial results, with worldwide revenue of $388.2 million, GAAP fully diluted EPS of $1.11, and adjusted fully diluted EPS of $1.55. The company also announced a definitive agreement for Curium US Holdings LLC to acquire all outstanding shares in an all-cash transaction valued at up to approximately $8.0 billion.

Why it matters — A LNTH watcher would care because the quarter's financials and the announced all-cash merger agreement with Curium, valued up to about $8.0 billion, represent major developments for the company's valuation and outlook.

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders

PRNewsWire · 3 Aug 2026negative

Ademi LLP is investigating Lantheus Holdings (NASDAQ: LNTH) for possible breaches of fiduciary duty and other violations of law related to its recently announced transaction with Curium. The law firm is seeking to determine whether the company is obtaining a fair price for public shareholders and is inviting shareholders to join the investigation.

Why it matters — LNTH watchers would care because the investigation questions whether the Curium transaction provides a fair price to public shareholders, potentially affecting the deal's outcome and shareholder value.

FAQ

Frequently asked questions about LNTH stock

What is the LNTH stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Lantheus Holdings, Inc. have a median 12-month price target of $105, with estimates ranging from $103 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LNTH stock a buy right now?

Of the 11 analysts covering Lantheus Holdings, Inc., 4 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lantheus Holdings, Inc. 88 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LNTH?

As at 15 Aug 2026, Lantheus Holdings, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will LNTH stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +4.0% from the last close, and Ticker Nerd's factor model ranks Lantheus Holdings, Inc. 88 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LNTH stock forecast for 2030?

No analyst covering Lantheus Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $115 over the next 12 months.

How has LNTH stock performed over the past year?

Lantheus Holdings, Inc. returned +85.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lantheus Holdings, Inc. do?

Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to assist clinicians in diagnosing and treating heart disease, cancer, and other conditions worldwide.

What is the latest news on LNTH?

The most recent item we track (Reuters, 14 Aug 2026): "US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment". The U.S. FDA approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company announced on Friday. The approval covers the agent's use in evaluating patients for the disease.

Company

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to assist clinicians in diagnosing and treating heart disease, cancer, and other conditions worldwide. Its portfolio includes DEFINITY, an injectable ultrasound enhancing agent for echocardiography; TechneLite, a technetium generator for nuclear medicine; Cardiolite for assessing heart muscle blood flow; PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent for prostate cancer lesions; Neurolite for stroke imaging; Xenon-133 for pulmonary function; and RELISTOR for opioid-induced constipation. The company also offers innovative AI-enabled solutions like PYLARIFY AI for quantitative PSMA PET/CT assessment, aPROMISE, Automated Bone Scan Index, and recent additions such as Flyrcado for heart blood flow evaluation, alongside expansions into Alzheimer's diagnostics through targeted radiodiagnostics. Lantheus Holdings, Inc. emphasizes precision medicine via strategic partnerships and biomarkers, serving oncology, cardiology, neurology, and non-oncologic sectors to enable clinicians to Find, Fight, and Follow disease. Founded in 1956 and headquartered in Billerica, Massachusetts, it plays a pivotal role in advancing radiopharmaceutical innovations.

CEO Ms. Mary Anne Heino · 1,193 employees · United States · https://www.lantheus.com